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SUMMARY
Mitochondrial diseases comprise a heterogeneous
group of genetically inherited disorders that cause
failures in energetic andmetabolic function. Boosting
residual oxidative phosphorylation (OXPHOS) activity
can partially correct these failures. Herein, using a
high-throughput chemical screen, we identified the
bromodomain inhibitor I-BET 525762A as one of the
top hits that increases COX5a protein levels in
complex I (CI) mutant cybrid cells. In parallel, bromo-
domain-containing protein 4 (BRD4), a target of
I-BET 525762A, was identified using a genome-wide
CRISPR screen to search for genes whose loss of
function rescues death of CI-impaired cybrids grown
under conditions requiring OXPHOS activity for sur-
vival. We show that I-BET525762A or loss of BRD4 re-
modeled the mitochondrial proteome to increase the
levels and activity of OXPHOS protein complexes,
leading to rescue of the bioenergetic defects and
cell death caused by mutations or chemical inhibition
of CI. These studies show that BRD4 inhibition may
have therapeutic implications for the treatment of
mitochondrial diseases.
INTRODUCTION
Mutations in themitochondrial or nuclear DNA that compromises
the oxidative phosphorylation (OXPHOS) system lead to a
spectrum of debilitating or even fatal human disorders known
as mitochondrial diseases (Koopman et al., 2012). Among
them, mitochondrial complex I (CI) deficiency is the most com-
mon OXPHOS defect observed in patients, and to date no cure
is available (Pfeffer et al., 2013; Swalwell et al., 2011). The impair-
ment of OXPHOS due to dysfunction in the electron transport
chain (ETC) compromises ATP production (Nunnari and Suoma-
lainen, 2012) and, depending on the mutation or insult, increases
the generation of reactive oxygen species (ROS) (Lin et al., 2012;
Vafai and Mootha, 2012) and unbalances the NAD+ to NADH
ratio due to NADH accumulation (Karamanlidis et al., 2013).
Proposed metabolic strategies to correct mitochondrial CI
deficiencies include using mitochondria-targeted antioxidant
molecules (Koopman et al., 2016) or biochemically bypassing
the defective complex—for example, using succinate (Pfeffer
et al., 2013) or short-chain quinones (idebenone or CoQ1) (Hae-
feli et al., 2011) that can feed electrons into the ETC downstream
of CI.
The validity of striving to boost residual mitochondrial activity to
overcome bioenergetic defects has recently been strengthened
by several studies reporting that overexpressing the transcrip-
tional coactivator PGC-1a (a knowncentral regulator ofmitochon-
drial biogenesis) partially corrects pathological phenotypes and
extends survival in mouse models with ETC deficiencies (Dillon
et al., 2012; Srivastava et al., 2007; St-Pierre et al., 2006). Based
on these findings, a possible approach to overcome ETC defi-
ciencies is to enhance the functional OXPHOS capacity which is
the failing hallmark of these diseases.
Bromodomain-containing protein 4 (BRD4) is a member of the
bromodomain and extraterminal domain (BET) family of proteins,
comprised of BRD2–BRD4 and BRDT (Nicodeme et al., 2010).
BET proteins contain two tandem bromodomains (protein mod-
ules that bind to acetyl-lysines) and an extraterminal domain
(ETD) that mediates protein-protein interactions (Dhalluin et al.,
1999). BRD4 binds to acetylated histones and coordinately re-
cruits additional proteins via its ETD to promoters and distal en-
hancers to modulate gene expression (Liu et al., 2013). Chemical
inhibitors to the BET family such as I-BET 525762A and JQ1,
which occupy the epsilon acetyl-lysine binding pocket of BRD4
and prevent its association to acetylated histones at the chro-
matin, have been effective in treating several cancer types (Daw-
son et al., 2011; Delmore et al., 2011; Filippakopoulos et al.,
2010). However, it is unknown whether BRD4 can control genes
linked to energy metabolism and impact ETC deficiencies.
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Figure 1. BRD4 Is Identified by Both High-Throughput Chemical and CRISPRGenetic Screens as a Target to Enhance OXPHOS Proteins and
Rescue Mitochondrial Bioenergetic Defects
(A) Schematic of high-throughput chemical screen.
(B) Scatterplot of chemicals tested (blue) plotted with first test (x axis) and repeated test (y axis) of COX5a fluorescent values relative to the average PGC-
1a-positive control (green). DMSO baseline fluorescent values (black) are indicated. Vertical dotted line indicates compounds selected at the 70% cutoff.
(C) COX5a fluorescent values from selected compounds tested in secondary screen plotted relative to PGC-1a positive control set to 1.0. Values represent the
mean ± SEM. n = 3.
(legend continued on next page)
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Here we have identified BRD4 using a mitochondrial-based
high-throughput chemical screen and tandem-genome wide-
CRISPR screen in humanCImutant cybrid cells. BRD4 inhibition,
either chemically or genetically, rescues mitochondrial bioener-
getics, protecting against cell death caused by CI defects. Dele-
tion or inhibition of BRD4 enhances OXPHOS genes, proteins,
and activity, increasing FADH2 levels to bypass defective CI.
These studies show that BRD4 inhibition corrects mitochondrial
CI deficiencies and may have therapeutic implications for the
treatment of mitochondrial diseases.
RESULTS
Identification of a Bromodomain Inhibitor and BRD4 in
High-Throughput Chemical and Genome-wide CRISPR
Screens
In order to discover chemical compounds that rescue bioener-
getic defects caused by mitochondrial disease mutations
through increases of mitochondrial proteins, we designed and
developed a high-throughput in-cell enzyme-linked immuno-
assay using human cybrid cells carrying a mutation (3796 A>G,
found in adult onset dystonia) in the mitochondrial-encoded pro-
tein ND1—an integral component of the NADH dehydrogenase
CI subunit (Simon et al., 2003) (Figure 1A). A diverse library of
10,015 chemical compounds were screened in duplicate, and
values were normalized to cells expressing PGC-1a—a tran-
scriptional regulator of mitochondrial biogenesis (Puigserver
et al., 1998; Wu et al., 1999) as a positive control (Figure 1B).
CIV was the most responsive to PGC-1a-stimulation; therefore,
the quantitative measurement of the CIV subunit COX5a served
as the readout. A 70% threshold was established to select top
hits for re-test using the same assay. Interestingly, the com-
pound with the highest score was I-BET 525762A, a pan-BET in-
hibitor that targets the BET family of proteins including BRD2–
BRD4 and BRDT (Nicodeme et al., 2010) (Figures 1C and 1D).
In parallel, and to complement this chemical screen, we per-
formed a genome-wide editing CRISPR screen. We used the
standard cell-death-based clinical assay to culture ND1 mutant
cybrid cells in media with galactose instead of glucose. Galac-
tose is unable to provide sufficient levels of ATP from glycolysis,
so cells are forced to depend on OXPHOS (Aguer et al., 2011;
Robinson et al., 1992). Thus, ND1 mutant cells in galactose me-
dia die within 72 hr while ND1 control cells survive (Figure 1E and
Figure S1A, available online). The genome-wide CRISPR screen
was performed with ND1 mutant cybrids to discover genes
whose loss of function would confer cell viability under galactose
conditions, presumably by boosting mitochondrial OXPHOS ca-
pacity. The screen employed a validated pooled lentiviral sgRNA
library targeting 18,675 genes in the human genome with
coverage of four sgRNAs per gene (Doench et al., 2016) (Fig-
ure 1E). We scored sgRNAs for enrichment within the pool
following growth in galactose media (Figure 1F). Remarkably,
in alignment with the chemical screen, one of the highest scoring
genes with high fold enrichment and statistical significance was
the bromodomain-containing protein 4 (BRD4)—a target that is
inhibited by I-BET 525762A. To further confirm these results,
we repeated the screen using more stringent conditions, chal-
lenging the cells with a second round of growth in galactose me-
dia to select persistently galactose-resistant cells. Again, BRD4
emerged as one of the highest scoring genes (Figures S1B and
S1C). Together, potent hits from these two independent and un-
biased screens (chemical and genome-wide CRISPR library)
converging to BRD4 strongly points toward BRD4 inhibition as
a mechanism to increase OXPHOS proteins (COX5a) and rescue
bioenergetic defects caused by mitochondrial CI mutations.
Bromodomain Inhibition Enhances OXPHOS
Protein Activity and Protects against Cell Death in
CI-Defective Cells
To validate and extend the impact of bromodomain inhibition
on mitochondrial energetic function, we tested its effects on
OXPHOS protein levels in ND1 mutant cybrids. I-BET 525762A
increased COX5a and an array of other OXPHOS protein levels
in a dose-responsive manner (Figures 2A and 2B) with increases
persisting at thewhole-complex level (Figure 2Cand Figure S2A).
Additional BRD4 inhibitors with diverse chemical structures,
such as JQ1 (Filippakopoulos et al., 2010), GSK1210151A (Daw-
son et al., 2011), and MS436 (Zhang et al., 2013), also increased
COX5a protein levels (Figure 2D). Indeed, comprehensive prote-
omics analysis indicated that I-BET treatment significantly
enhanced proteins involved in mitochondrial OXPHOS, transla-
tion, and organization (Figure 2E; Table S1). The increase in pro-
tein levels proved to be functional, as treatment with the I-BET
525762A compound enhanced both total oxygen consumption
and the activity of ETC complexes II (CII) and IV (CIV) (Figures
3A–3C). I-BET 525762A treatment did not alter glycolysis as
measured by ECAR, and mitochondrial complex activity for
complex III (CIII) and complex V (CV) was unchanged (Figures
S2B–S2D). To assess whether the increase in mitochondrial
oxidative capacity from bromodomain inhibitors was sufficient
to rescue cell death caused by mitochondrial bioenergetic defi-
cits, ND1 mutant cells were cultured in galactose instead of
glucose. Vehicle-treated cells died when exposed to galactose
for 72 hr, but strikingly, treatment with I-BET 525762A or other
bromodomain inhibitors rescued galactose-induced cell death,
and cells proliferated for several passages (Figures 3D, 3E,
S1A, and S2E). Interestingly, the bromodomain inhibitor also
prevented galactose-induced cell death and enhanced oxygen
consumption in other mitochondrial CI-deficient human cybrid
cells such as Leber hereditary optic neuropathy (LHON), which
carries the G14459A mutation in ND6 (Jun et al., 1994) (Figures
3F and 3G) and knockdown of two different CI subunits, NDUFS3
and NDUFV2 (Figure 3H). The energetic rescue by the bromodo-
main inhibitor was observed not only in CI mutant cybrid cells but
also in fibroblasts derived from patients harboring a mutation in
ACAD9, a chaperone protein necessary for CI activity (Nouws
(D) Chemical structure of the I-BET 525762A compound with COX5a fluorescent values below.
(E) Workflow of genome-wide CRISPR screen.
(F) Scatterplot of two replicate CRISPR screens showing enrichment of sgRNAs after galactose treatment. Points highlighted in red represent the different
sgRNAs for BRD4. See also Figure S1.
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et al., 2010) (Figure 3I). I-BET 525762A also displayed rescue
in cells that were chemically inhibited by rotenone (Figure 3J).
I-BET-mediated rescue was only observed in CI-deficient cells.
Other complex-deficient cells such asMELAS (mitochondrial en-
cephalomyopathy and stroke-like episodes A3243G-Leucine
tRNA), MERRF (myoclonic epilepsy and ragged red fibers
A8344G-Lysine tRNA), COX10 KO (heme A:farnesyltransferase
cytochrome c oxidase assembly factor), and Reiske KO (CIII as-
sembly protein) displayed no rescue when cultured in galactose
media despite comparable basal oxygen consumption levels
(Figures S2F and S2G). These results indicate that bromodo-
main inhibitors remodel the mitochondrial proteome, increasing
oxidative activity and readjusting bioenergetic defects caused
by CI deficiency.
A B
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Figure 2. Bromodomain Inhibition Increases OXPHOS Proteins and Remodels the Mitochondrial Proteome
(A) I-BET 525762A increases OXPHOS proteins (left). Cycs densitometry of IBET-treated ND1-mutated cybrids is comparable to PGC-1a-positive control (right).
(B) I-BET 525762A increases OXPHOS proteins in a dose-responsive manner.
(C) Blue native PAGE I-BET 525762A treatment increases OXPHOS complex levels.
(D) Diverse BRD4 inhibitors increase OXPHOS proteins. Immunoblots shown are representative of greater than three independent experiments.
(E) Proteomic heatmap of the hierarchical clustering of all proteins (4,800) in duplicate (left). I-BET 525762A-upregulated proteins (> 1.4-fold) are indicated
(vertical black bar). Proteomic heatmap indicating that I-BET treatment in ND1-mutated cybrids increases core ETC proteins compared to control (middle). Gene
Ontology (GO) categories from upregulated proteins enriched after Benjamin-Hochberg correction are indicated to the right. Corresponding log10 p values (x axis)
and the number of proteins (in parentheses) are listed. See also Figure S2 and Table S1.
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Figure 3. Bromodomain Inhibition Increases Mitochondrial Bioenergetics and Protects against Galactose-Induced Cell Death
(A–C) Total oxygen consumption (A) as well as CII (B) and CIV (C) activities are increased with I-BET 525762A. CS indicates citrate synthase.
(D) I-BET 525762A protects against galactose-induced cell death. Microscopy image (left) is representative of at least three independent experiments, and time
course (top right) and cell number quantification (bottom right) are the mean ± SEM, n = 3. Asterisks denote *p < 0.05 or **p < 0.01 via Student’s t test. The
horizontal black scale bar represents 200 mm.
(E) Different BRD4 inhibitors rescue ND1-mutated cybrids from galactose-induced cell death.
(F and G) I-BET 525762A enhances oxygen consumption in ND6-mutated LHON cybrids (F) and protects against galactose-induced cell death (G).
(H) I-BET 525762A rescues galactose-induced cell death in CI knockdown control cells.
(I) I-BET 525762A protects against galactose-induced cell death in ACAD9 human-patient-derived fibroblasts. Microscopy image (right) is representative of at
least three independent experiments, and cell number quantification (left) is the mean ± SEM, n = 3. The horizontal black scale bar represents 200 mm.
(J) I-BET525762Aprotectsagainstgalactose-inducedcelldeath incontrolhumancybridswith rotenone-inducedCIdeficiency.Data represent themean±SEM,n=3.
Asterisks denote *p < 0.05 or **p < 0.01 via Student’s t test. All I-BET andBRD4 inhibitor treatments are delivered at final concentration of 0.9 mM. See also Figure S2.
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BRD4 Controls the Mitochondrial OXPHOS Program
We next investigated whether abrogation of BRD4 could in-
crease mitochondrial function in ND1mutant cells. BRD4 protein
was ablated using different sgRNAs and shRNAs; consistent
with the I-BET 525762A treatment, sgBRD4-expressing guides
and shBRD4 constructs enhanced OXPHOS protein levels (Fig-
ure 4A and Figure S3A). In addition, total oxygen consumption
and respiratory CII and CIV activities were increased (Figures
A B C
D G
E H
F I
Figure 4. Loss of Function of BRD4 Enhances Mitochondrial Bioenergetics while Gain of Function Impairs OXPHOS Capacity
(A) CRISPR ablation of BRD4 enhances OXPHOS proteins.
(B) Total oxygen consumption rates are increased in sgBRD4 ND1 human cybrids compared to sgNeg control.
(C and D) Complex II (C) and complex IV (D) activities are increased in sgBRD4 ND1 human cybrids compared to sgNeg controls. CS indicates citrate synthase.
(E) Representative microscopy image (right) of sgNeg, sgBRD4, and IBET-treated sgNeg ND1 mutant cybrids cultured in galactose for 72 hr. Cell quantification
after 72 hr in galactose media is indicated to the left. The horizontal black scale bar represents 200 mm.
(F) Competition assay. GFP-negative sgBRD4 is more abundant that GFP-positive sgNeg in ND1-mutated cybrids.
(G) BRD4 overexpression in control human cybrids reduces OXPHOS proteins.
(H) Total oxygen consumption is reduced with BRD4 overexpression in control human cybrids.
(I) Control human cybrids are sensitized to galactose-induced cell death with BRD4 overexpression. Immunoblots shown are representative of at least three
independent experiments, and all other experiments are the mean ± SEM, n = 3. Asterisks denote *p < 0.05 or **p < 0.01 via Student’s t test. All I-BET treatments
are delivered at final concentration of 0.9 mM. See also Figure S3.
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4B–4D and Figure S3B). Consistent with I-BET treatment, CIII
and CV activities were unaltered in sgBRD4 guides (Figures
S3C and S3D). As predicted based on the CRISPR screen,
BRD4-ablated cells were protected from galactose-induced
cell death (Figure 4E). These results were confirmed using
selective competition between sgNeg (GFP+) and sgBRD4
(GFP)-expressing ND1mutant cells. After 72 hr with galactose,
98% of the surviving cells were GFP, indicating that BRD4
ablation conferred a selective advantage under these energy-
restricted conditions (Figure 4F). To further support the BRD4
function in mitochondrial energetics, we overexpressed BRD4
in control human cybrid cells. Ectopic expression of BRD4,
conversely to its ablation or inhibition, reduced OXPHOS protein
levels and decreased total oxygen consumption compared to
the levels found in controls (Figures 4G and 4H). In addition,
increased expression of BRD4 in control cybrids impaired cell
growth under galactose conditions (Figure 4I). These findings
indicate that changes in the expression of BRD4 protein alter
mitochondrial energetic capacity and cell survival under nutrient
conditions that require OXPHOS.
Displacing the BRD4 Protein from Nuclear-Encoded
OXPHOS Promoters Increases OXPHOS Genes
We next evaluated the mechanisms whereby BRD4 inhibition
increases mitochondrial oxidative function. Bromodomain pro-
teins bind to chromatin through interaction with histone-acety-
lated lysines (Dhalluin et al., 1999), and I-BET-525762A disrupts
this interaction by occupying the ε-amino lysine pocket, lead-
ing to direct bromodomain protein displacement from chromatin
(Nicodeme et al., 2010). To assess whether BRD4 localizes
at promoters of nuclear-encoded mitochondrial genes, we
analyzed published datasets containing BRD4 ChIP sequence
results (Anders et al., 2014). Genes containing BRD4-binding
peaks within 1,000 bp upstream and downstream of the tran-
scription start site (TSS) were identified using a BETA-minus al-
gorithm andwere functionally classified using gene ontology and
Panther algorithm (Wang et al., 2013; Zhang et al., 2008). Inter-
estingly, these data displayed BRD4 occupancy at promoters
of genes linked to the OXPHOS pathway comparable to the
BRD4 occupancy found in the control gene CCND2 (Anders
et al., 2014) (Figures S4A and S4B). These findings were vali-
dated in ND1 mutant cells through analysis of BRD4 occupancy
at promoters of nuclear-encodedmitochondrial genes, including
SDHD, CYCS, and COX5A. As expected, BRD4 inhibition by
I-BET-525762A decreased BRD4 occupancy at these promoters
(Figures 5A and S4C). Intriguingly, displacement of BRD4 by the
I-BET compound led to enhanced occupancy of PGC-1a, a tran-
scriptional coactivator that binds to promoters and activates
expression of mitochondrial genes (Charos et al., 2012) (Fig-
ure 5B). Much like the BRD4 inhibitor, ectopic expression of
PGC-1a strongly displaced BRD4 from these promoters (Fig-
ure 5C). Consistent with these results, expression of mitochon-
drial genes was increased in ND1 mutant cells when BRD4
was displaced from OXPHOS gene promoters by I-BET
525762A (Figures 5D and S4D) or depleted with CRISPR or
shRNA (Figures 5E and S4E). This is in contrast to the BRD4
target CCND2, a gene repressed by the BRD4 inhibitor (Fig-
ure S4D). Conversely, ectopic expression of BRD4 decreased
the expression of OXPHOS genes (Figure 5F). To further confirm
these findings, PGC-1a was depleted from ND1-mutated cy-
brids. PGC-1a knockdown prevented the I-BET-mediated in-
crease in mitochondrial transcripts and partially blunted the
rescue from galactose-induced cell death (Figures 5G and 5H).
These data suggest that BRD4 occupancy at nuclear-encoded
promoters regulates the expression of mitochondrial genes
and prevents PGC-1a, and likely other activators, from binding.
Inhibition of BRD4 Rewires Bioenergetic Metabolism
through CII to Overcome CI Deficiency
To gain additional insight into the mechanism of I-BET-mediated
enhancement of OXPHOS bioenergetic capacity and protection
from galactose-induced cell death, a comprehensive meta-
bolomics analysis was performed (Figure 6A). Intriguingly,
metabolites such as dihydroxyacetone phosphate (product of
mitochondrial glycerol-3-phosphate dehydrogenase) and fuma-
rate (product of succinate dehydrogenase) were significantly
enhanced in I-BET-treated ND1 cybrids compared to DMSO
controls (Figures 6A–6C). Also interestingly, these two enzymes
are able to bypass the defective CI in the ND1-mutated cells by
supplying electrons via FADH2 to CII and CoQ to maintain ATP
levels. Indeed, I-BET 525762A treatment in ND1 human cybrids
prevented galactose-induced declines in the energetic metabo-
lite ATP and normalized NADH (which accumulates due to CI
deficiency (Karamanlidis et al., 2013) to similar levels as control
cells (Figures 6D, 6E,S5A, and S5B). Consistent with increases
in metabolites converging to CII and CoQ, FAD levels were
elevated in cells treated with the bromodomain inhibitor (Fig-
ure 6F), suggesting increased utilization of FADH2. Given that
galactose-derived pyruvate is not an optimal substrate for oxida-
tion due to the defective CI, we speculated that the increase in
oxygen consumption in I-BET-treated ND1 mutant cybrids was
accomplished by oxidizing alternative energy sources such as
glutamine, which enters the I-BET-enhanced CII via the TCA cy-
cle. Indeed, I-BET 525762A treatment increased 14C glutamine
oxidation and was able to moderately prevent cell death when
glutamine was the main carbon source (Figures 6G and 6H).
In addition, I-BET treatment enhanced genes in the glutamine
utilization pathway (Figure S5C). In contrast, I-BET 525762A
failed to prevent galactose-induced cell death when glutamine
was either removed or the glutaminase enzyme (which catalyzes
glutamine to glutamate conversion) was chemically blocked
(Figures 6H and 6I). Taken together, these results show that
I-BET 525762A augments both glutamine oxidation and the
metabolites that generate FADH2. FADH2 can be oxidized
through increased CII and CIV activities to produce ATP and
rescue cell death. To assess whether CII is required for I-BET
525762A-induced survival, we genetically abrogated CII function
using two shRNAs targeting the SDHA subunit to disrupt both
the ETC and TCA cycle. Interestingly, I-BET 525762A-mediated
cell rescue was considerably minimized in knockdown cells
placed under galactose for 72 hr (Figure 6J). To further test
whether increases in mitochondrial oxidative activity—mediated
via BRD4 inhibition—are necessary to maintain bioenergetics
and cell survival in CI-deficient cells, we used two different ap-
proaches to completely disrupt mitochondrial respiration: chlor-
amphenicol, an antibiotic that blocks mitochondrial protein
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Figure 5. IBET 525762A Treatment Displaces BRD4 from OXPHOS Promoters and Increases Transcription in CI-Deficient Cells
(A) ChIP assay. I-BET 525762A displaces BRD4 from nuclear-encoded mitochondrial promoters. Negative control promoter region Atp1A3 is unaltered.
(B) ChIP assay. PGC-1a occupancy increases upon I-BET 525762A-mediated BRD4 displacement.
(C) ChIP assay. BRD4 is displaced upon adPGC-1a overexpression. Data are representative of mean ± SEM, n = 3. Asterisks denote *p < 0.05 or **p < 0.01 via
Student’s t test.
(D–F) I-BET 525762A-mediated displacement of BRD4 (D) and ablation of BRD4 by CRISPR (E) increases expression of OXPHOS genes, while overexpression of
BRD4 decreases OXPHOS gene expression (F). Data represent mean ± SEM, n = 3. Asterisks denote *p < 0.05 or **p < 0.01 via Student’s t test.
(G and H) ShPGC-1a KD in ND1-mutated cybrids fails to increase OXPHOS transcripts (G) and partially blunts rescue from galactose-induced cell death (H) when
treated with I-BET 525762A. See also Figure S4.
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translation, and ethidium bromide (EtBr), which causes mito-
chondrial DNA depletion. In both cases, the levels of MT-CO1,
a mtDNA encoded-protein translated by mitochondrial ribo-
somes and essential for respiration (Tsukihara et al., 1996),
were undetectable (Figures S5D and S5E). I-BET 525762A failed
to rescue galactose-induced cell death in chloramphenicol or
EtBr-treated cells (Figures S5D and S5E). In summary, these re-
sults indicate that I-BET 525762A-induced mitochondrial respi-
ration is necessary to rescue the bioenergetic defects and main-
tain survival in human cybrids with mitochondrial CI mutations.
DISCUSSION
Cells harboring mitochondrial mutations in CI fail to cope with
excessive energetic demands and undergo cell death. In princi-
ple, a metabolic reprogramming that increases ETC activity and
bypasses mutated CI could rescue the bioenergetic defects and
maintain cell survival. Our studies have identified that the inhibi-
tion of BRD4 plays a regulatory role in this metabolic reprogram-
ming. BRD4 binds to nuclear-encodedmitochondrial genes, and
its inhibition efficiently rewires cellular energetics caused by CI
defects (Figure 6K). BRD4 inhibition remodels the mitochondrial
proteome and causes changes in metabolic routes that increase
and utilize FADH2, transferring electrons to the respiratory chain
downstream of CI and increasing ATP.
Metabolic strategies to reprogram and bypass ETC defects
inmitochondrial diseasemutations have been based onCoQ de-
rivatives or NAD+ precursors, but their efficacy has been limited,
particularly in CI deficiencies (Pfeffer et al., 2013). Bromodomain
inhibitors might overcome these metabolic limitations by acting
through a broad, mitochondrial-based gene-expression pro-
gram that generates energetic, efficient mitochondria to bypass
CI defects. Thus, coordinated increases in CII and CIV through
BRD4 inactivation would allow oxidation of substrates such
as glutamine, fatty acids, or branched-chain amino acids,
increasing the FADH2 that will enter the ETC at CII or CoQ sites.
Mounting evidence demonstrates that oxidizing glutamine can
serve as the major substrate for energy production (Lu et al.,
2010; Reitzer et al., 1979). We show that, in addition to OXPHOS
genes, transcripts linked to glutamine metabolism are also upre-
gulated by I-BET treatment, which supports the role of glutamine
catabolism and ATP production by BRD4 inhibition in CI-defi-
cient mutant cells. Consistent with this demonstration of ener-
getic and metabolic rescue via BRD4 inhibition, previous studies
have corrected CI deficiency by introducing the Saccharomyces
cerevisiae NADH-quinone oxidoreductase (NDI1) protein to
bypass the defective CI and increase OXPHOS and ATP produc-
tion from CIII and CIV (Bai et al., 2001).
A metabolic hallmark of CI malfunction is NADH accumulation
caused by reduction in CI-dependent NADH reductase activity
(Karamanlidis et al., 2013). Increased NADH might alter catalytic
activityofNAD+-dependent enzymessuchassirtuins, TCAcycles,
or glycolytic dehydrogenases (Nunnari and Suomalainen, 2012).
We show that NADH levels are partially restored after bromodo-
main inhibition and may contribute to bioenergetic rescue in
CI-deficient cells.Althoughacompletemechanismofhowbromo-
domain inhibition normalizes NADH is unknown, some putative
candidates, such as mitochondrial GPD2 (glycerol phosphate
dehydrogenase), emerged in the proteomic analysis and were
elevated in isolated mitochondria from I-BET-treated samples
(Figure 2E). GPD2 is a mitochondrial, membrane-bound protein
that forms part of the glycerol-phosphate shuttle that transfers
cytosolic NADH to FADH2 and bypasses CI inhibition (Mra´cek
et al., 2013). The accumulated mitochondrial NADH caused by
the defective CI could be transported to the cytosolic compart-
ment using themalate-aspartate pathway toprovide the substrate
for the glycerol-phosphate shuttle (Gut andVerdin, 2013). Further-
more, metabolomic analysis shows that several metabolites
related to cellular redox states and antioxidant response were
increased by I-BET treatment. Deleterious phenotypes caused
byCI failure havebeenshown toarisewhen increased reactiveox-
ygen species (ROS) levels and compromised ATP generation are
present (Haefeli et al., 2011). Thus, increases inROSdetoxification
through bromodomain inhibition might also contribute to the bio-
energetic rescue and survival caused by defective CI.
In these studies, I-BET 525762A was extremely effective in
increasing OXPHOS capacity and promoting survival under
nutrient-restrictive galactose conditions in cells with CI disrup-
tion. I-BET, however, was unable to rescue MELAS and MERRF
cybrid cells harboring other mitochondrial complex mutations. It
would appear that I-BET 525762A can only provide rescue when
the defective complexes occur at an early point in the ETC,
such that these complexes can be bypassed to boost residual
OXPHOS capacity. Given that CIV levels and activity are also
increased upon I-BET treatment, it is conceivable that BRD4 in-
hibition, similar to PGC-1a expression (Srivastava et al., 2009),
would positively impact mutations in which CIV is not fully abla-
ted. A basal threshold of ETC activity seems to be indispensable
for bromodomain inhibitors to rescue bioenergetic defects and
promote survival, as shown in the experiments using chloram-
phenicol or EtBr cells (Figures S5D and S5E).
BRD4 is a chromatin-bound transcriptional regulator linked to
expression of genes associated with different biological pro-
cesses, including tumor progression or inflammation (Baratta
et al., 2015; Huang et al., 2009). However, how and whether
these programs integrate with mitochondrial energetics and
metabolic control is unknown. As a scaffolding protein, BRD4 re-
cruits activator or repressor complexes to target promoters. Its
activator function has been extensively characterized through in-
teractions with pTEFb, Mediator, and JMJD6, all of which pro-
mote RNA polymerase II (Pol II) elongation (Liu et al., 2013).
When displaced from chromatin by bromodomain inhibitors,
this corresponds to a decrease of target genes such as MYC
(Delmore et al., 2011). BRD4, however, can also be incorporated
into repressor complexes as demonstrated in the human papillo-
mavirus (HPV) system (Wu et al., 2006). Chromatin-bound BRD4
recruits and binds to the HPV viral protein E2 and prevents the
binding of TFIID and Pol II to the target promoters leading to
gene repression. Genome-wide RNA sequencing analysis of
BRD4 abrogation reveals a dual role of BRD4, either in increasing
or decreasing mRNA transcripts (Shu et al., 2016). BRD4 oc-
cupies nuclear-encoded mitochondrial promoters, and its inhib-
itor, I-BET 525762A, significantly reduces BRD4 occupancy at
the mitochondrial promoters. Our results indicate that I-BET-
mediated gene repression occurs almost immediately after
I-BET treatment; however, activation of OXPHOS genes occurs
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Figure 6. I-BET 525762A Treatment Rewires and Enhances Metabolic and Energetic States of CI-Deficient Cells
(A) Metabolomics heatmap in control and ND1-mutated cybrids in duplicate. I-BET 525762A-treated ND1-mutated human cybrids increasemetabolites linked to
energy, CII, CoQ, and redox metabolism.
(B and C) I-BET 525762A treatment increases dihydroxyacetone phosphate (B) and succinyl CoA (C) metabolite levels.
(D–F) I-BET 525762A treatment increases ATP (D), NAD+ (E), and FAD (F) metabolite levels in ND1-mutated cybrids. Data represent mean ± SEM, n = 2.
(G) 14C Glutamine oxidation is enhanced by I-BET 525762A treatment in ND1-mutated cybrids.
(H) I-BET-mediated galactose rescue is blunted when glutamine is removed from culture media in ND1-mutated cybrids.
(legend continued on next page)
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over a longer time point. These time-dependent differences be-
tween I-BET-mediated gene repression and activation could be
attributed to the difference in the dynamic recruitment and com-
position of transcription factors to these promoters. Increased
transcription of OXPHOS genes suggests that BRD4 competes
with a potent activator and may also be associated with a
repressor protein. Given that (1) the displacement of BRD4
from nuclear-encoded mitochondrial promoters increased the
occupancy of potent transcriptional activators such as PGC-1a
(Figure 5B), and (2) I-BET-mediated increase in OXHPOS genes
and cell survival under galactose conditions was greatly
impeded with PGC-1a knockdown, our current data would
seem to suggest a competition model (Jang et al., 2005; Wall-
berg et al., 2003). The involvement of a repressor protein or an
alternate mechanism, however, may also be plausible, as there
was partial, albeit significantly blunted, rescue in ND1-mutated
cybrids upon I-BET treatment in the context of PGC-1a knock-
down under galactose conditions.
The ability of bromodomain inhibition to correct bioenergetic
defects caused by deficient CI activity through different meta-
bolic strategies may be employed as a possible avenue to treat
mitochondrial and neurodegenerative diseases in which the inhi-
bition of CI has been associated with disease progression.
EXPERIMENTAL PROCEDURES
High-Throughput Chemical Screening
A total of 1.03 106 humanND1mutant (3796 A >G) cybrid cells were seeded in
a 384-well plate (Corning, 3712) and incubated for 24 hr at 37C with 5% CO2.
Positive control wells (column 24) were infected with adenoviral Pgc-1a and
negative control lanes (column 23) and received 0.3%DMSO. Following a me-
dia change, chemical compounds were added to experimental wells via pin
transfer, and cells were incubated with compound for 24 hr at 37C with 5%
CO2. The In-Cell ELISA (ICE) protocol was then performed. Cells were washed
with PBS (HyClone) prior to being fixed with 4% paraformaldehyde (Santa
Cruz, sc281692) and permeabilized with 0.2% Triton X-100 (Sigma, X100).
Cells were washed twice with PBS and treated with Alexa Fluor 680 succini-
midyl ester (Thermo Fisher, A37567) for internal control before blocking with
blocking buffer (LI-COR, 927-40000) and incubating with COX5a antibody
(Abcam, ab110262) for 16 hr at 4C. Cells were then washed with 0.2% Triton
X-100 in PBS before the addition of the secondary anti-mouse IRDye 800CW
antibody (LI-COR, 926-32212) for 1 hr. Fluorescence was then quantified using
the LI-COR Aerius instrument and software. Values in the 800 channel were
normalized to the respective internal control (700 channel). Normalized data
were then expressed as a ratio to the average positive control (set to 100%).
Further details for screening methods are available on request.
Design and Creation of the CRISPR Library
The human genome-wide lentipool CRISPR library was designed and created
as previously described (Doench et al., 2016)
Genome-wide CRISPR Screen
A total of 1.13 108 human ND1 mutant (3796 A > G) cybrid cells, which stably
expressed Cas9, were seeded in 38 150 mm 3 25 mm dishes (3.0 3 106 per
dish). Cells were infected with the lentipooled library to achieve a 30%–50%
infection efficiency, corresponding to a multiplicity of infection (MOI) of
0.3–0.5. Media was changed 24 hr later, and 0.5 ug/mL puromycin was
added 48 hr later and selected for 7 additional days. Cells were trypsinized
and separated into 150 mm 3 25 mm dishes (4.0 3 106 per dish). The next
day, cells were washed twice with PBS, and media was changed to non-
glucose DMEM with glutamine (4 mM) supplemented with 10 mM galactose
(Sigma D7050), 10% FBS, 1% P/S, and 1 mM pyruvate. Cells were cultured
for 5 days in galactose media. After 5 days, galactose media was replaced
with high-glucose DMEM in order to expand the remaining cells. Cells were
maintained and passaged in glucose DMEM for 2 weeks before genomic
DNA was isolated from two biological replicates using QIAamp DNA mini kit
(QIAGEN 51304). A third independent experiment was performed as described
above, but this time cells were challenged with two rounds of 10mMgalactose
treatment.
Illumina Sequencing
Samples were submitted and sequenced at the Broad Institute using a Hi-
Seq2000 (Illumina) as previously described (Doench et al., 2016).
Screen Analysis and Statistics
For analysis, the log2-fold change of each sgRNA was normalized to the start-
ing plasmid DNA (pDNA) pool for each biological replicate unless otherwise
stated. Each sgRNA was ranked by log2-fold change, and this number was
then divided by the total number of sgRNAs in the pool to determine a
percent-rank value. These percent-rank values from two biological replicates
were represented as scatterblots. A third independent experiment using more
stringent culture conditions was analyzed equally but represented as a bar
graph. In order to performRIGER and STARS analysis, the percent-rank values
across subpools were merged. STARS analysis allows the calculation of
p values, FDR, and q value (corrected FDR) for hit genes. STARS is written
in Python, and is publicly available: http://www.broadinstitute.org/rnai/
public/software/index.
Cell Culture and Treatments
All cell lines were maintained in high-glucose DMEM (HyClone), 10% FBS, and
1%P/S at 37C and 5%CO2. For compound treatment, cells were seeded at a
density of 1.03 105 cells per well in a 6-well plate (Falcon, 353046) and allowed
to adhere for 24 hr before treatment with 0.9 mM I-BET 525762A, JQ1,
GSK1210151A, MS436 chemical compounds, or vehicle control for 24 hr in
high-glucose DMEM. For galactose experiments, cells were seeded in 6-well
plates grown in high-glucose DMEM, 10% FBS, and 1% P/S at 37C
and 5% CO2 for 24 hr to allow cells to adhere. Cells were then washed
twice with PBS andmedia was changed to DMEMwith no glucose but supple-
mented with 4 mM glutamine (HyClone) and 10 mM galactose (Sigma G0750),
10% FBS, and 1% P/S. Cells were incubated in galactose-containing
media ± 0.9 mM I-BET 525762A for 72 hr with daily media changes. Galactose
media included 50 mM BPTES (Sigma SML0601) for experiments assessing
glutamine requirement. Cells were then trypsinized and quantified using
a hemocytometer (NanoEnTek, DHC-N01). Generation of RhoO cells in-
volved treating control cybrids with high-glucose DMEM supplemented with
50 ng/mL of ethidium bromide (Bio-Rad 1610433) and 50 mg/mL of uridine
(Sigma U3750) for 2 weeks with media changes every 48 hr. To abrogate mito-
chondrial protein translation, control cybrids were treated with high-glucose
DMEM supplemented with 40 mM chloramphenicol (Sigma C0378) and
50 mg/mL uridine for 5 days with daily media changes. Mitochondrial protein
depletion for both ethidium bromide and chloramphenicol treatments were
(I) Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) at 25 mM, which selectively inhibits Glutaminase (GLS1) to block glutamine to glutamate
conversion, abolished the positive effects of I-BET 525762A in ND1-mutated cybrids.
(J) I-BET 525762A displays minimal rescue upon SDHA knockdown. Immunoblot indicates complete SDHA knockdown at the protein level. Data represent the
mean ± SEM, n = 3. Asterisks denote *p < 0.05 or **p < 0.01 via Student’s t test. All I-BET treatments are delivered at a final concentration of 0.9 mM.
(K) Model detailing how BRD4 inhibition rescues bioenergetic defects in CI-deficient cells. Arrows indicate metabolites that were increased (green) or decreased
(red) upon I-BET 575762A treatment. Abbreviations are as follows: aKG, alpha-ketoglutarate; G-3-P, glyceraldehyde-3-phosphate; F-1-6-P, fructose 1,6 bi-
sphosphate; and CoQ, coenzyme Q. See also Figure S5.
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assessed bymeasuringMT-CO1 protein level. Cells were then placed in galac-
tose media (described above) in the presence or absence of 0.9 mM I-BET for
72 hr. For rotenone treatments, control cybrid cells were seeded in high-
glucose DMEMwith 0.8 nM rotenone (Sigma 8875) in the presence or absence
of 0.9 mM I-BET 525762A for 5 days with daily media changes. Cell quantity
was assessed by cell counting after treatment. For selective competition
assay, 5 3 104 of sgNeg (GFP+) and sgBRD4 (GFP) ND1 cybrid cells (1 to
1) were plated together in a 6-well plate and cultured in galactose media (pre-
viously described). Cells were trypsinized and analyzed by FACS (BD FACS
Canto II) daily for 3 consecutive days. The ratio between sgNeg (GFP+) and
sgBRD4 (GFP) was calculated. Transfections for gain- and loss-of-function
studies were performed according to the manufacturer’s instructions using
the polyfect reagent (QIAGEN, 301107). The following constructs were used:
pLJM1-sgBRD4.1, 50-GAGCAGGTATTGCAGTTGGT-30; pLJM1-eGFP (addg-
ene 19319); pLKO.1 shBRD4, 50-CCGGCCTGGAGATGACATAGTCTTACTC
GAGTAAGACTATGTCATCTCCAGGTTTTTG-30 (Sigma); pLKO.1 shSDHA.1,
50-GATTTGCTGATGGAAGCATAA-30, pLKO.1 shShSDHA.2, 50-TCGCTAT
TGCACACCTTATAT-30; pLKO.1 shNDUFS3, 50-TTTGTTCCTGCTCGCAAT
AAC-30; pLKO.1 shNDUFV2, 50-CCAGTTGGAAAGTATCACATT-30, pLKO.1
shPGC-1a 66, 50-CCGGTATGACAGCTACGAGGAATATCTCGAGATATTC
CTCGTAGCTGTCATATTTTTG-3’; pLKO.1 shPGC-1a 85, 50- CCGGCCGT
TATACCTGTGATGCTTTCTCGAGAAAGCATCACAGGTATAACGGTTTTT-3’;
pLKO.1 shCTR; pLX-GFP; pLX-BRD4 (Human ORFeome 71377); and lenti-
CRISPR v2 (addgene 52951). Guide sequences for Brd4 were as follows:
sgBrd4.1, 50-GAGCAGGTATTGCAGTTGGT-30; and sgBrd4.2, 50- ACTGCAA
TACCTGCTCAGAG-30.
SUPPLEMENTAL INFORMATION
Supplemental information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.molcel.2016.08.023.
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